tbuckley/cabot-search huggingface dataset:
Abnormal Chromosome Signals Myelocytic Leukemia
Authors: K O GOH
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Children’s heart surgery website aims to end confusion over survival rates
Authors: Matthew Limb
Journal: BMJ (2016)

Researchers have launched a website to help end public “confusion and alarm” about survival data on children’s heart surgery outcomes in the United Kingdom and Ireland. They said that the government, scientists, companies, and other bodies should do more to make health statistics understandable to patients and their families.

The website, Understanding Children’s Heart Surgery Outcomes,1 which is supported by the charity Sense about Science, explains the 30 day survival rate after children’s heart surgery. The charity’s director, Tracey Brown, said that “overinterpretation of faulty data” in 2013 had caused alarm for patients’ families and the temporary closure of Leeds General Infirmary’s paediatric heart unit.

“This …
LSD1 Impairs the Epithelial-Mesenchymal Transition (EMT) and Osteoclastogenesis Potency in Multiple Myeloma and Synergistically Induces Cytotoxicity with HDAC Inhibitors
Authors: Maria Gkotzamanidou, Mariateresa Fulciniti, Jesús Martín Sanchez, Mehmet Kemal Samur, Giovanni Parmigiani, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2014)
EPIG-08DOWNREGULATION OF miR-379/miR-656 CLUSTER (C14MC) IN OLIGODENDROGLIOMAS WITH POSSIBLE MECHANISTIC AND CLINICOPATHOLOGICAL IMPLICATIONS
Authors: Anupam Kumar, Subhashree Nayak, Pankaj Pathak, Suvendu Purkait, Supriya Mallick, Vaishali Suri, M.C. Sharma, Vivek Tandon, B.S. Sharma, Ashish Suri, Arijit Mukhopadhyay, Chitra Sarkar
Journal: Neuro-Oncology (2015)

MicroRNAs(miRNAs) are often grouped into clusters in the genome, and dysregulation of miRNA clusters has been shown in various cancers. miR-379/miR-656 cluster(C14MC) is located within an imprinted chromosomal region, Dlk1-Dio3 locus, which also harbours the non-coding, maternally expressed gene MEG3. MEF2 and JUN have been reported as key transcription regulators for C14MC. Downregulation of C14MC has been observed in several CNS tumors, including GBM. However, the status and clinicopathological significance of C14MC in Oligodendrogliomas(ODGs) are unexplored. Therefore, expression of 47 miRNAs from C14MC was analyzed in 45 ODGs(24 Grade II, 21 Grade III) and 10 controls using customized TaqMan low density array microfluidic assay(TLDA). Further, its expression was correlated with clinicopathological data. Expression of MEF-2, JUN and MEG3 were examined by RT-PCR. Significant downregulation of C14MC was observed in 90% of ODGs. 19 miRNAs were differentially expressed between both the grades, indicating a diagnostic role. Methylation data analysis showed hyper-methylation of the genomic region encompassing the C14MC(beta value-0.9; p < 0.05), which was further substantiated by significant downregulation of MEG3 expression. Treatment of HS683 cells(anaplastic ODG cell line) with DNA-demethylating agent 5-azacytidine resulted in up-regulation of three(miR-485-5p, -369-3p, -382; p < 0.05) out of six randomly selected miRNAs. These results suggest that C14MC locus is possibly under epigenetic regulation in ODGs. In addition, downregulation of MEF2 and JUN, suggest that deregulation of C14MC in ODGs may be attributed to repression of these transcription factors. Further, two miRNAs(miR-656, -487b; p < 0.04) correlated with better progression-free survival, indicating their prognostic significance. This is the first report demonstrating the silencing of the second largest microRNA cluster in ODGs, implicating its tumor-suppressive role in their pathogenesis, along with diagnostic and prognostic significance. The hypermethylation of C14MC along with downregulation of MEG3, MEF2 and JUN could be the possible mechanisms for C14MC downregulation in ODG, independently or in synergy.
Abstract A09: CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Authors: Dan Wu, Xinyi Guo, Jing Su, Ruoying Chen, Dmitriy Berenzon, Keith Bonin, Martin Guthold, Weiling Zhao, Xiaobo Zhou
Journal: Clinical Cancer Research (2015)

Abstract As the second most prevalent hematologic malignancy, multiple myeloma (MM) remains incurable and relapses due to intrinsic or acquired drug resistance. Therefore, new therapeutic strategies that target molecular mechanisms responsible for drug resistance are attractive. Interactions of tumor cells with their surrounding microenvironment impact tumor initiation, progression and metastasis, as well as patient prognosis. This cross-talk is bidirectional. Tumor cells can also attract or activate tumor-associated stromal cells by releasing cytokines to facilitate their growth, invasion and metastasis. The effect of myeloma cells on bone marrow stromal cells (BMSCs) has not been well studied. In current study, we determined the effect of myeloma cells on the stiffness of BMSCs and explored the molecular mechanisms underlying these mechanical changes. Cell stiffness measurements were performed using a combined atomic force microscope (AFM)/inverted optical microscope. We found that higher stiffness of BMSCs was not a unique characteristic of BMSCs from MM patients (M-BMSCs). BMSCs from MGUS (Monoclonal gammopathy of undetermined significance) patients were also stiffer than the BMSCs from healthy volunteers (N-BMSCs). The stiffness of M-BMSCs was enhanced when cocultured with myeloma cells. In contrast, no changes were seen in myeloma cell-primed MGUS- and N-BMSCs. Interestingly, our data indicated that CD138- myeloma cells, but not CD138+ cells, regulated M-BMSC stiffness. SDF-1 was highly expressed in the CD138- myeloma subpopulation compared with that in CD138+ cells. Inhibition of SDF-1 using AMD3100 or knocking-down CXCR4 in M-BMSCs blocked CD138- myeloma cells-induced increase in M-BMSC stiffness, suggesting a crucial role of SDF-1/CXCR4. AKT inhibition attenuated SDF-1-induced increases in M-BMSC stiffness. These findings demonstrate, for the first time, CD138- myeloma cell-directed cross-talk with BMSCs and reveal that CD138- myeloma cells regulate M-BMSC stiffness through SDF-1/CXCR4/AKT signaling. Citation Format: Dan Wu, Xinyi Guo, Jing Su, Ruoying Chen, Dmitriy Berenzon, Keith Bonin, Martin Guthold, Weiling Zhao, Xiaobo Zhou. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A09.
Performance of standardized BEAMing platform for detecting RAS mutations in the blood of metastatic colorectal cancer (mCRC) patients.
Authors: Frederick S. Jones, Dan Edelstein, Katharina Wichner, Carina Ross, Kristin Stieler, Verena Boehm, Eva Lenfert, Jessica Bien, Antje Lukas, Jerzy Macioszek
Journal: Journal of Clinical Oncology (2016)

11538 Background: Expanded RAS testing with BEAMing has been shown to improve the identification of mCRC patients eligible for anti-EGFR therapy as evidenced by results of 1,218 patients from CRYSTAL, OPUS and CALGB/SWOG 80405 studies. Although RAS testing is typically performed on tumor specimens, a standardized approach has not been established and turnaround times are variable. Moreover, in metastatic patients, tumor molecular heterogeneity obscures accurate RAS status and surveying of multiple tissue sites is impractical. To overcome these challenges, a standardized BEAMing platform to perform RAS mutation analysis from circulating tumor DNA (ctDNA) was developed for patient testing in the clinical laboratory and its performance was evaluated. Methods: ctDNA from 205 mCRC patients recruited at centers in the US and Europe was tested with the OncoBEAM RAS CRC kit that detects 34 separate mutations in KRAS/NRAS codons 12, 13, 59, 61, 117, 146. Concordance was determined by comparing plasma RAS mutation results to those from time matched tumor samples using the local standard of care (SOC) method. Comprised of patients with newly diagnosed and recurrent disease, this cohort is representative of the anti-EGFR therapy intended use population. Discrepancies in RAS results between matched plasma and tumor samples were evaluated with tissue BEAMing. Results: Plasma ctDNA testing with the OncoBEAM RAS CRC kit showed a high degree of concordance with 189 of 205 (92.2%) cases having equivalent RAS mutation status as that determined from tumor tissue, 104 of 115 (90.4%) showing positive percent agreement, and 85 of 90 cases showing negative percent agreement (94.4%). Discrepancy evaluation revealed significant RAS result variability between current SOC techniques. Conclusions: Results from ctDNA testing using the OncoBEAM RAS CRC kit compares favorably with tissue-based RAS mutation testing. It is thus a viable alternative for determining eligibility of CRC patients for anti-EGFR therapy. Moreover, plasma ctDNA may have utility in monitoring patients experiencing relapse, as the detection of emergence/disappearance of mutations may be indicative of response to targeted therapy.
Distribution, Oxygenation, and Clonogenicity of Macrophages in a Murine Tumor
Authors: Peggy L. Olive
Journal: Cancer Communications (1989)

Transplantable murine tumors, such as the squamous cell carcinoma growing in C3H mice, include a significant proportion of normal cells. The nature of these cells, their locations relative to the blood supply, their oxygenation status, and ability to incorporate 3H-thymidine were examined by sorting cells staining positive or negative with fluorescein isothiocyanate-conjugated goat antimouse IgG. Of the cells that were recovered from this tumor, 39% +/- 19 (n = 25) were IgG+ cells, and this percentage was independent of tumor sizes greater than 0.2 g and less than 1 g. Cells staining positive (i.e., containing the Fc receptor for the IgG molecule) were diploid, non-clonogenic cells. More than 95% of the cells that bound the antibody rapidly phagocytosed latex microspheres, indicating that the host cells in the tumor were primarily macrophages. The negative-staining cells were more than 90% near-tetraploid. Macrophages were distributed randomly through the tumor cord. Both tumor cells and macrophages incorporated 3H-thymidine, with greater incorporation by larger cells close to the functional tumor blood vessels. Conversely, in cells distant from the blood supply, binding of the hypoxia probe misonidazole was enhanced in both macrophages and tumor cells, and the rates of metabolism of misonidazole were similar for both. Removing macrophages prior to plating tumor cells in vitro had no obvious effect on tumor cell viability after treatment of mice with x-rays or Adriamycin.
Distribution of N-Acetyl-2-Aminofluorene in the Rat Following a Single Feeding&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: H P MORRIS, B B WESTFALL
Journal: JNCI Journal of the National Cancer Institute (1948)

Distribution of N-Acetyl-2-Aminofluorene in the Rat Following a Single Feeding Get access Harold P. Morris, Harold P. Morris Search for other works by this author on: Oxford Academic PubMed Google Scholar Benton B. Westfall Benton B. Westfall National Cancer Institute, National Institutes of Health, Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 3, December 1948, Pages 149–154, https://doi.org/10.1093/jnci/9.3.149 Published: 01 December 1948 Article history Received: 12 April 1948 Published: 01 December 1948
Low Frequency and Poor Prognosis Of MLL-Partial Tandem Duplications In Pediatric Acute Myeloid Leukemia Using MLPA Method: The Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 Trial
Authors: Kentaro Ohki, Myoung-ja Park, Hitoshi Sano, Yusuke Hara, Norio Shiba, Daisuke Tomizawa, Takashi Taga, Akiko Moriya Saito, Junichiro Fujimoto, Akio Tawa, Keizo Horibe, Souichi Adachi, Yasuhide Hayashi
Journal: Blood (2013)
Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study
Authors: Alexander Kunz, Martin Ebinger, Frederik Geisler, Michal Rozanski, Carolin Waldschmidt, Joachim E Weber, Matthias Wendt, Benjamin Winter, Katja Zieschang, Jochen B Fiebach, Kersten Villringer, Hebun Erdur, Jan F Scheitz, Serdar Tütüncü, Kerstin Bollweg, Ulrike Grittner, Sabina Kaczmarek, Matthias Endres, Christian H Nolte, Heinrich J Audebert
Journal: The Lancet Neurology (2016)
Transparent-Chamber Observations of the Response of a Transplantable Mouse Mammary Tumor to Local Roentgen Irradiation
Authors: Ruth Merwin, Glenn H. Algire, Henry S. Kaplan
Journal: JNCI Journal of the National Cancer Institute (1950)

Transparent-Chamber Observations of the Response of a Transplantable Mouse Mammary Tumor to Local Roentgen Irradiation Ruth Merwin, Ruth Merwin Search for other works by this author on: Oxford Academic PubMed Google Scholar Glenn H. Algire, Glenn H. Algire National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Henry S. Kaplan Henry S. Kaplan Department of Radiology, Stanford University School of Medicine, San Francisco 15, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 3, December 1950, Pages 593–623, https://doi.org/10.1093/jnci/11.3.593 Published: 01 December 1950 Article history Received: 24 November 1950 Published: 01 December 1950
Bio-inspired in situ crosslinking and mineralization of electrospun collagen scaffolds for bone tissue engineering
Authors: Chetna Dhand, Seow Theng Ong, Neeraj Dwivedi, Silvia Marrero Diaz, Jayarama Reddy Venugopal, Balchandar Navaneethan, Mobashar H.U.T. Fazil, Shouping Liu, Vera Seitz, Erich Wintermantel, Roger W. Beuerman, Seeram Ramakrishna, Navin K. Verma, Rajamani Lakshminarayanan
Journal: Biomaterials (2016)
House Republicans release plan to replace Affordable Care Act
Authors: Michael McCarthy
Journal: BMJ (2016)

Republicans in the US House of Representative have released a plan1 that they say would replace the Affordable Care Act. The plan includes reforms that would give consumers more choices at lower costs and assure that “every American had access to quality, affordable health care.”

Supporters of the 2010 health reform law derided the proposal, saying that after promising for nearly six and half years to repeal and replace the law, the Republicans have submitted a proposal filled with old, “recycled ideas,” and have provided no details on cost, how it would be paid for, or how many people it would cover. They said that most of the proposals would benefit the healthy and well off, leaving the poor …
Targeting the Over-Expressed Transcription Factor Yin-Yang 1 (YY1) Sensitizes Resistant Multiple Myeloma (MM) Cell Lines to Apoptosis by Bortezomib or Melphalan,
Authors: Hong Liu, Sara Huerta-Yepez, Clara M. Rivera-Pazos, Ma de Lourdes Cabera-Muñoz, Stavroula Baritaki, Suzie Vardanyan, Manuel L Penichet, Haiming Chen, James R. Berenson, Benjamin Bonavida
Journal: Blood (2011)
Circadian Influence on Metabolism and Inflammation in Atherosclerosis
Authors: Cameron S. McAlpine, Filip K. Swirski
Journal: Circulation Research (2016)

Many aspects of human health and disease display daily rhythmicity. The brain’s suprachiasmic nucleus, which interprets recurring external stimuli, and autonomous molecular networks in peripheral cells together, set our biological circadian clock. Disrupted or misaligned circadian rhythms promote multiple pathologies including chronic inflammatory and metabolic diseases such as atherosclerosis. Here, we discuss studies suggesting that circadian fluctuations in the vessel wall and in the circulation contribute to atherogenesis. Data from humans and mice indicate that an impaired molecular clock, disturbed sleep, and shifting light–dark patterns influence leukocyte and lipid supply in the circulation and alter cellular behavior in atherosclerotic lesions. We propose that a better understanding of both local and systemic circadian rhythms in atherosclerosis will enhance clinical management, treatment, and public health policy.
Cardiopulmonary resuscitation with interposed abdominal compression.
Authors: Babbs Cf, Tacker Wa
Journal: Circulation (1986)

The addition of interposed abdominal compressions (IACs) to otherwise standard CPR enhances artificial circulation both in anesthetized dogs with ventricular fibrillation and in electrical models of the circulation that demonstrate fundamental mechanisms generating flow. Manual abdominal compressions cause both central aortic and central venous pressure pulses but, because of differences in venous and arterial capacitance, the former are usually greater than the latter. Thus mean perfusion pressure is enhanced. Limited clinical studies confirm that IAC-CPR can improve perfusion pressures in humans, and reported complications of the technique are rare in animals and man. However, no study has demonstrated that IAC-CPR improves either short- or long-term survival after cardiac arrest in man. Accordingly, the method remains experimental and cannot be recommended for basic life support at the present time.
Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines
Authors: Sheng Guo, Wubin Qian, Jie Cai, Likun Zhang, Jean-Pierre Wery, Qi-Xiang Li
Journal: Cancer Research (2016)

Abstract The Cancer Genome Atlas (TCGA) project has generated abundant genomic data for human cancers of various histopathology types and enabled exploring cancer molecular pathology per big data approach. We developed a new algorithm based on most differentially expressed genes (DEG) per pairwise comparisons to calculate correlation coefficients to be used to quantify similarity within and between cancer types. We systematically compared TCGA cancers, demonstrating high correlation within types and low correlation between types, thus establishing molecular specificity of cancer types and an alternative diagnostic method largely equivalent to histopathology. Different coefficients for different cancers in study may reveal that the degree of the within-type homogeneity varies by cancer types. We also performed the same calculation using the TCGA-derived DEGs on patient-derived xenografts (PDX) of different histopathology types corresponding to the TCGA types, as well as on cancer cell lines. We, for the first time, demonstrated highly similar patterns for within- and between-type correlation between PDXs and patient samples in a systematic study, confirming the high relevance of PDXs as surrogate experimental models for human diseases. In contrast, cancer cell lines have drastically reduced expression similarity to both PDXs and patient samples. The studies also revealed high similarity between some types, for example, LUSC and HNSCC, but low similarity between certain subtypes, for example, LUAD and LUSC. Our newly developed algorithm seems to be a practical diagnostic method to classify and reclassify a disease, either human or xenograft, with better accuracy than traditional histopathology. Cancer Res; 76(16); 4619–26. ©2016 AACR.
Office Visits Prior to Screening Colonoscopy—Reply
Authors: Kevin R. Riggs, Eun Ji Shin, Jodi B. Segal
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conception Control with Norethynodrel: Progress Report of Four-Year Field Study at Humacao, Puerto Rico
Authors: A P SATTERTHWAITE, C J GAMBLE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doctors need to adopt “realistic” medicine, says Scotland’s chief medical officer
Authors: Bryan Christie
Journal: BMJ (2016)

Scotland’s chief medical officer wants the profession to take a critical look at modern practice and abandon the outdated “doctor knows best” culture by better supporting patients in taking informed decisions about their own treatment.

In her first annual report since taking over the role, Catherine Calderwood has called for a debate among doctors about modern medicine, which she says may be causing hidden harm through overtreatment.1 She wants to establish a system of “realistic” medicine where …